The antiarrhythmic treatment of atrial fibrillation

Drug and Therapeutics Bulletin

Volumn 34, Issue 6, 1996, Pages 41-45

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; FLECAINIDE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; VERAPAMIL; WARFARIN;

AGRANULOCYTOSIS; CARDIOVERSION; CLINICAL TRIAL; CONSTIPATION; CORNEA DISEASE; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HEART ATRIUM FIBRILLATION; HEPATITIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG FIBROSIS; LUPUS ERYTHEMATOSUS; NAUSEA; ORAL DRUG ADMINISTRATION; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; SHORT SURVEY; SINUS RHYTHM; THROMBOEMBOLISM; THYROID DISEASE; TORSADE DES POINTES; URINE RETENTION;

EID: 0029922630     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.1996.34641     Document Type: Short Survey

References (34)

1. Warfarin or aspirin for non-rheumatic atrial fibrillation? DTB 1994; 32: 57-60.
2. Wheeldon NM. Atrial fibrillation and anticoagulant therapy. Eur Heart J 1995; 16: 302-12.
3. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation. The Framingham Study. N Engl J Med 1982, 306: 1018-22.
4. Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-68.
5. Alam M, Thorstrand C. Left ventricular function in patients with atrial fibrillation before and after cardioversion. Am J Cardiol 1992; 69: 694-6.
6. Gosselink ATM, Crijns HJGM, Van Den Berg MP et al. Functional capacity before and after cardioversion of atrial fibrillation: a controlled study Br Heart J 1994; 72: 161-6.
7. Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68: 41-6.
8. Mancini GBJ, Goldberger AL. Cardioversion of atrial fibrillation: consideration of embolization, and coagulauon, prophylactic pacemaker, and long-term success. Am Heart J 1992; 104: 617-21.
9. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion A meta-analysis of randomized control trials. Circulation 1990; 82: 1106-16.
10. Suttorp MJ, Kingma JH, Lie-A-Huen L, Mast EG. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 1989; 63: 693-6.
11. Borgeat A, Goy J-J, Maendly R, Kaufmann U, Grbic M, Sigwart U. Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1986; 58: 496-8.
12. Teo KK, Harte M, Horgan JH. Sotalol infusion in the treatment of supraventricular tachyarrhythmias. Chest 1985; 87: 113-8.
13. Brodsky MA, Allen BJ, Walker, III CJ, Casey TP, Luckett CR, Henry WL. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987; 60: 572-5.
14. Gosselink ATM, Crijns HJGM, Van Gelder IC, Hillige H, Wiesfeld ACP, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992, 267: 3289-93.
15. Faniel R, Schoenfeld PH. Efficacy of i.v. amiodarone in converting rapid atrial fibrillation and flutter to sinus rhythm in intensive care patients. Eur Heart J 1983; 4: 180-5.
16. Committee on Safety of Medicines/Medicines Control Agency. Amiodarone (Cordarone X). Curr Prob Pharmacovigil 1996; 22: 3-4.
17. Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J Am Coll Cardiol 1995; 25: 452-9.
18. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest 1995; 108 (suppl): 352-9S.
19. Crijns HJ, Van Gelder IC, Van Gilst WH, Hillege H, Gosselink AM, Lie KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991; 68: 335-41.
20. Karlson BW, Torstensson I, Abjorn C, Jansson S-O, Peterson L-E. Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. Eur Heart J 1988; 9: 284-90.
21. Van Gelder IC, Crijns HJGM, Van Gilst WH, Van Wijk LM, Hamer HPM, Lie KI. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989; 64: 1317-21.
22. Graboys TB, Podrid PJ, Lown B. Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. Am Heart J 1983; 106: 870-6.
23. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990; 82: 1932-9.
24. Anderson JL, Gilbert EM, Alpert BL et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989; 80: 1557-70.
25. UK Propafenone PSVT Study Group. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation 1995; 92: 2550-7.
26. Reimold SC, Cantillon CO, Friedman PL, Antman EM, Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993; 71: 558-63.
27. Hohnloser SH, Woosley RL. Sotalol. N Engl J Med 1994; 331: 31-8.
28. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992; 20: 527-32.
29. Bigger, Jr JT. Digitalis toxicity. J Clin Pharmacol 1985; 25: 514-21.
30. Jelliffe RW, Brooker G. A nomogram for digoxin therapy. Am J Med 1974; 57: 63-8.
31. Matsuda M, Matsuda Y, Yamagishi T et al. Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation. Cardiovasc Res 1991; 25: 453-7.
32. Benfield P, Sorkin EM. Esmolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1987; 33: 392-412.
33. Lundstrom T, Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol 1990; 16: 86-90.
34. Feld GK, Fleck RP, Fujimura O, Prothro DL, Bahnson TD, Ibarra M. Control of rapid ventricular response by radiofrequency catheter modification of the atrioventricular node in patients with medically refractory atrial fibrillation. Circulation 1994; 90: 2299-307.